Results Published: Randomized Trial for Self-administered vs DOT Once-Weekly Isoniazid and Rifapentine Treatment of Latent TB Infection

Results from the iAdhere trial conducted through the TB Trials Consortium have been published in the Annals of Internal Medicine. This randomized trial aimed to compare treatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observation. Enrollment sites were located in the US, Spain, Hong Kong, and South Africa; Vanderbilt and the Metro Nashville Health Department participated in enrollment.

The results of this study support using self-administered, once-weekly isoniazid and rifapentine to treat latent TB infection in the United States, and such treatment could be considered in similar settings when DOT is not feasible.


Article: Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial

Editorial: Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families

Study and Editorial Summary: Self-administered treatment appears effective for latent tuberculosis